TGFB1 and neoplasm: Notably, activation of the TGF‐β/Smad signalling pathway in the hypoxic TME tends to reduce T‐cell glycolytic competitiveness194; therefore, the knockdown of TGF‐βR2 in CAR‐Ts inhibits TGF‐β signalling to facilitate CAR‐T survival in vivo and increase the tumour elimination efficacy.195, 196, 197